

1 **Identification of a rapidly-spreading triple mutant for high-level metabolic insecticide resistance in**  
2 ***Anopheles gambiae* provides a real-time molecular diagnostic for anti-malarial intervention**  
3 **deployment.**

4 Harun Njoroge<sup>1,2</sup>, Arjen van't Hof<sup>1</sup>, Ambrose Oruni<sup>1,3</sup>, Dimitra Pipini<sup>1</sup>, Sanjay C. Nagi<sup>1</sup>, Amy Lynd<sup>1</sup>, Eric R.  
5 Lucas<sup>1</sup>, Sean Tomlinson<sup>1</sup>, Xavi Grau-Bove<sup>1</sup>, Daniel McDermott<sup>1</sup>, Francis T. Wat'senga<sup>4</sup>, Emile Z.  
6 Manzambi<sup>4</sup>, Fiacre R. Agossa<sup>5</sup>, Arlette Mokuba<sup>5</sup>, Seth Irish<sup>6</sup>, Bilali Kabula<sup>7</sup>, Charles Mbogo<sup>8,9</sup>, Joel  
7 Bargul<sup>10,11</sup>, Mark J.I. Paine<sup>1</sup>, David Weetman<sup>1</sup> and Martin J. Donnelly<sup>1,12,\*</sup>

8 <sup>1</sup>Department of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3  
9 5QA, UK.

10 <sup>2</sup>Kenya Medical Research Institute (KEMRI) Centre for Geographic Medicine Coast, KEMRI-Wellcome  
11 Trust Research Programme, Kilifi, Kenya

12 <sup>3</sup>College of Veterinary Medicine, Animal Resources & Bio-security, Makerere University, Kampala,  
13 Uganda

14 <sup>4</sup>Institut National de Recherche Biomédicale, PO Box 1192 Kinshasa, Democratic Republic of Congo.

15 <sup>5</sup>USAID President's Malaria Initiative, VectorLink Project, Abt Associates, 6130 Executive Blvd, Rockville,  
16 MD 20852, USA.

17 <sup>6</sup>U.S. President's Malaria Initiative and Centers for Disease Control and Prevention, 1600 Clifton Road  
18 NE, Atlanta, GA 30329, USA

19 <sup>7</sup>Amani Research Centre, National Institute for Medical Research, Muheza, Tanzania

20 <sup>8</sup>Population Health Unit, KEMRI-Wellcome Trust Research Programme, Nairobi

21 <sup>9</sup>KEMRI-Centre for Geographic Medicine Research Coast, Kilifi

22 <sup>10</sup>Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya

23 <sup>11</sup>The Animal Health Department, International Centre of Insect Physiology and Ecology, Nairobi, P.O.  
24 Box 30772-00100, Kenya

25 <sup>12</sup>Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1RQ, UK.

26 \*Corresponding author:

27 Department of Vector Biology, Liverpool Tropical School of Medicine, Pembroke Place, Liverpool, L3

28 5QA, UK. Telephone +44 151 705 3296, E-mail [martin.donnelly@lstm.ac.uk](mailto:martin.donnelly@lstm.ac.uk)

29 **Abstract**

30 Insecticide resistance provides both an increasingly pressing threat to the control of vector-borne  
31 diseases and insights into the remarkable capacity of natural populations to show rapid evolutionary  
32 responses to contemporary selection. Malaria control remains heavily dependent on deployment of  
33 pyrethroid insecticides, primarily in long lasting insecticidal nets (LLINs), but resistance in the major  
34 malaria vectors has increased over the last 15 years in concert with dramatic expansion of LLIN  
35 distributions. Identifying genetic mechanisms underlying high-level resistance in mosquitoes, which may  
36 almost entirely overcome pyrethroid efficacy, is crucial for the development and deployment of  
37 potentially resistance-breaking tools. Using the *Anopheles gambiae* 1000 genomes (Ag1000g) data we  
38 identified a very recent selective sweep in mosquitoes from Uganda which localized to a cluster of  
39 cytochrome P450 genes, including some commonly implicated in resistance. Further interrogation  
40 revealed a haplotype involving a trio of mutations, a nonsynonymous point mutation in *Cyp6p4* (I236M),  
41 an upstream insertion of a partial Zanzibar-like transposable element (TE) and a duplication of the  
42 *Cyp6aa1* gene. The mutations appear to have originated recently in *An. gambiae* from the Kenya-  
43 Uganda border region around Lake Victoria, with stepwise replacement of the double-mutant (Zanzibar-  
44 like TE and *Cyp6p4-236M*) with the triple-mutant haplotype (including *Cyp6aa1* duplication), which has  
45 spread into the Democratic Republic of Congo and Tanzania. The triple-mutant haplotype is strongly  
46 associated with increased expression of genes able to metabolise pyrethroids and is strongly predictive  
47 of resistance to pyrethroids most notably deltamethrin, a commonly-used LLIN insecticide. Importantly,  
48 there was increased mortality in mosquitoes carrying the triple-mutation when exposed to nets co-  
49 treated with the synergist piperonyl butoxide (PBO). Frequencies of the triple-mutant haplotype remain  
50 spatially variable within countries, suggesting an effective marker system to guide deployment decisions  
51 for limited supplies of PBO-pyrethroid co-treated LLINs across African countries. Duplications of the  
52 *Cyp6aa1* gene are common in *An. gambiae* across Africa and, given the enzymes metabolic activity, are  
53 likely to be a useful diagnostic for high levels of pyrethroid resistance.

54

55

## 56 Introduction

57 Insecticide resistance in disease vectors has become an influential model for understanding rapid  
58 contemporary evolution but, more importantly, identifying how resistance arises and spreads is crucial  
59 for disease control. Resistance to pyrethroid insecticides in African malaria vector mosquitoes has  
60 spread to near ubiquity [1, 2] and, though it is often difficult to demonstrate its impact on malaria  
61 infections [3], in some cases it has reached levels that threaten the effectiveness of vector control  
62 programmes [4, 5]. A better understanding of resistance distribution and mechanisms will permit a  
63 more informed selection and deployment of insecticides to combat evolving mosquito populations.  
64 Whilst our understanding of the genetic basis of insecticide resistance in mosquitoes has advanced  
65 substantially [6], especially in the important vector *Anopheles funestus* [7], molecular diagnostics for the  
66 major vectors in the *An. gambiae* complex remain limited to a handful of mutations[8] which explain a  
67 relatively small fraction of the variance in phenotype [9, 10] or which are now at such high frequency as  
68 to provide limited diagnostic resolution [11].

69

70 Long-lasting insecticidal nets (LLINs) are the principal tool for vector control to combat malaria,  
71 especially in sub-Saharan Africa [12]. The majority of LLINs are treated only with pyrethroid insecticides,  
72 to which resistance is now widespread [13]. Though behavioural variation and physical or physiological  
73 modifications affecting insecticide uptake may sometimes play a role, pyrethroid resistance is caused  
74 predominantly by two distinct mechanisms. The first is resistance via point mutations in the target-site  
75 of the insecticide, for pyrethroids the Voltage-gated sodium channel (*Vgsc*), which results in decreased  
76 sensitivity to the insecticide [14]; the second is metabolic resistance due to over-expression or altered  
77 activity of detoxification enzymes, of which the cytochrome P450 family is commonly considered most  
78 important [15, 16]. Cytochrome P450 activity is inhibited by the synergist piperonyl-butoxide (PBO), and  
79 bed nets incorporating PBO are effective against P450-mediated resistance, as demonstrated by large-  
80 scale field trials [4, 17]. Given the continued operational use of pyrethroid-containing nets, it is vital that  
81 we understand the genetic mechanisms that may impact their efficacy, to optimise bednet deployment,  
82 preferably using information from rapidly-applied DNA markers. In advance of a randomized control trial  
83 of PBO-LLINs [4], we sought to characterise pyrethroid resistance mechanisms in the primary malaria  
84 vector *An. gambiae* s.s. [18] in Uganda and Kenya.

85

86 The recent development of the *Anopheles gambiae* 1000 genomes project (Ag1000g) has led to a step

87 change in our ability to identify DNA variation driven by selection pressure. We have been able to  
88 perform genome-wide searches for regions under recent natural selection in insecticide resistant  
89 populations across Africa, and work has shown that the strongest selective sweeps in the genome are all  
90 found around genes known to be important for resistance [6, 19]. Furthermore, a whole-genome scan of  
91 copy number variants (CNVs) in the Ag1000g data revealed that increases in gene copy number were  
92 highly enriched in clusters of detoxification genes, pointing to a potentially widespread mechanism for  
93 increased gene expression [20], which, in some cases, may elevate resistance. A number of gene  
94 duplications were observed around the *Cyp6aa/Cyp6p* gene family cluster on chromosome 2R, and the  
95 majority of these duplications included the gene *Cyp6aa1* (Figure 1). *Cyp6aa1* has been found to be  
96 overexpressed in pyrethroid resistant populations in congeneric species [21-23], but it has received very  
97 little attention compared to known insecticide-metabolizing genes such as *Cyp6m2* [24, 25], *Cyp6p3* [15]  
98 and *Cyp9k1* [26] and its importance in resistance in *An. gambiae* remains unknown.

99

100 In this study, we examine a strong selective sweep detected in the *Cyp6aa/Cyp6p* genomic region in  
101 samples of *An. gambiae* s.s. from Uganda and Western Kenya. We find that the sweep is closely  
102 associated with three mutations (a SNP in *Cyp6p4*, a duplication of *Cyp6aa1* and a partial transposable  
103 element insertion termed ZZB-TE) in tight physical and statistical linkage. The triple-mutant haplotype is  
104 associated with a high-level of pyrethroid resistance, most notably to deltamethrin. The three  
105 mutations appeared sequentially, leading to successive selective sweeps, with the triple-mutant  
106 haplotype replacing earlier variants and then spreading rapidly across East and Central Africa. We show  
107 that this haplotype is under positive selection and causes increased expression of key cytochrome P450s  
108 and through recombinant protein expression using both an *E. coli* and an *Sf9*-baculovirus system we  
109 show that both CYP6AA1 and CYP6P4 are capable of metabolizing pyrethroid insecticides.

110

## 111 **Methods**

### 112 **Interrogation of the Ag1000g dataset and identification of tagging markers**

113 Whole genome sequence data in the Ag1000g data set have previously revealed a strong selective  
114 sweep in Ugandan populations around the *Cyp6aa/Cyp6p* cluster [19] (Figure 1). An isoleucine to  
115 methionine substitution in codon 236 of CYP6P4 (see extended data Figure 10b in [19]) was identified  
116 provisionally as a swept haplotype tagging SNP. Previous work [20] had shown that a duplication of the  
117 *Cyp6aa1* gene was also observed in these samples (previously termed *Cyp6aap-Dup1*). To objectively  
118 determine how these mutations segregated with the observed selective sweep [19] we grouped the 206

119 Ugandan haplotypes (n=103 diploid individuals) by similarity using the 1000 SNPs located immediately  
120 upstream and downstream of the start of the *Cyp6aa/Cyp6p* gene cluster (500 non-singleton SNPs in  
121 each direction from position 2R:28,480,576). Distances were calculated with the *pairwise\_distance*  
122 function in *scikit-allel* [27] and converted to a nucleotide divergence matrix (*Dxy* statistic) by correcting  
123 the distance by the number of sequencing-accessible bases in that region. We defined clusters of highly  
124 similar haplotypes by hierarchical clustering with a cutoff distance of 0.001. This resulted in the  
125 identification of a cluster of 122 highly similar haplotypes. To determine whether the haplotype cluster  
126 showed signs of a selective sweep, we estimated the extended haplotype homozygosity (EHH) decay  
127 within each of the haplotype groupings, around two different focal loci: (i) the putative sweep SNP  
128 marker *Cyp6p4-236M* (2R:28,497,967 +/- 200 kbp; total 14,243 phased variants), and (ii) the 5 $\square$  and 3 $\square$   
129 breakpoints of the *Cyp6aap-Dup1* duplication (2R:28,480,189 - 200 kbp and 2R:28,483,475 + 200 kbp;  
130 total 14,398 phased variants). We used the *ehh\_decay* function of *scikit-allel* [27].

131 We also used the haplotype groupings identified above to calculate the Garud *H* statistics [28] and the  
132 haplotypic diversity at the *Cyp6aa/Cyp6p* cluster locus (coordinates 2R:28,480,576 to 2R:28,505,816).  
133 Specifically, we used the *moving\_garud\_h* and *moving\_haplotype\_diversity* functions in *scikit-allel* to  
134 obtain a series of estimates for each statistic in blocks of 100 variants located within the cluster, and  
135 used a block-jackknife procedure to calculate averages and standard errors of each estimate (*jackknife*  
136 function in *scikit-allel misc* module). Python scripts to reproduce these analyses are available  
137 <https://github.com/xgrau/cyp6-AgUganda> together with genomic variation data  
138 <https://www.malariagen.net/data/ag1000g-phase1-ar3.1>.

### 139 Molecular screening of colony and wild caught mosquitoes

140 Locked-nucleic acid (LNA) probe-based PCR diagnostics were designed for all three mutations  
141 (Supplementary materials Appendix 1).

142 Genotype:phenotype association testing was performed using two colonies of *An. gambiae* s.s., BusiaUG  
143 (resistant) and Mbita (susceptible). The BusiaUG strain was established in the lab in November 2018  
144 from Busia, eastern Uganda and exhibits high resistance to pyrethroids and organochlorines (<10%  
145 mortality following WHO exposure test), but full susceptibility to organophosphates and carbamates  
146 (Oruni *et al.* unpublished). The Mbita strain was first colonised from Mbita Point, Kenya in 1999, and is  
147 fully susceptible to pyrethroids. Colonies were reared in insectaries targeted to 25-27°C and 70-80%  
148 relative humidity.

149 Freshly emerged females from the Mbita line were mated with 3-5 day-old BusiaUG males and then  
150 blood fed. The offspring from this cross were then crossed back to the parental BusiaUG line. This design  
151 was chosen as resistance variants are often recessive. The resultant backcrossed 3-5-day-old females  
152 were exposed for one hour to deltamethrin, permethrin or  $\alpha$ -cypermethrin (the three insecticides most  
153 commonly used on LLINs) or DDT (a non-pyrethroid sodium channel antagonist), following WHO  
154 standard procedures. Mosquitoes were maintained on a 10% sugar solution after exposure and  
155 mortality was recorded 24 hours post exposure.

156 Democratic Republic of Congo. *Anopheles gambiae* s.s. were obtained from the President's Malaria  
157 Initiative supported entomological surveillance project [29] and from collections conducted by Lynd *et al*  
158 [30]. Mosquitoes were collected by human landing catch or pyrethrum spray collection from 15  
159 locations between 2013 and 2018. Resistance-phenotyped individuals were also obtained from  
160 Pwamba, Bassa and Fiwa in Nord Ubangi Province in 2016. These mosquitoes were assessed for  
161 susceptibility to deltamethrin or permethrin using a standard WHO tube assay or a cone bioassay where  
162 Permanet 3.0 (deltamethrin plus PBO) or Olyset Plus (permethrin plus PBO) were the test nets [23].  
163 Kenya and Uganda. Collection details for specimens from contiguous areas of western Kenya and  
164 eastern Uganda have been published previously [20, 24, 25]. Tanzania. Mosquito collections were  
165 conducted in Geita, Bagamoyo and Muleba districts of Tanzania in 2018.

166 Mosquitoes from all collections were genotyped at the ZZB-TE, *Cyp6p4-236M* and *Cyp6aap-Dup1* loci  
167 and genotype:phenotype association testing was performed by Fisher's exact tests.

## 168 **Analysis of temporal change**

169 The most complete time series of ZZB-TE, *Cyp6p4-236M* and *Cyp6aap-Dup1* allele frequencies were  
170 available from Kabondo, DRC; western Kenya and eastern Uganda. To model allele frequency changes  
171 over time we estimated the three parameters of the standard recursive population genetic model (allele  
172 frequency at time zero, selection coefficient and dominance coefficient) using a maximum likelihood  
173 approach assuming a binomial distribution: an approach previously applied to insecticide target-site  
174 resistance mutations [31]. The analysis was performed in R (<http://www.r-project.org>). An estimated  
175 generation time of one calendar month was used as in previous studies [31].

## 176 **Recombinant protein and insecticide metabolism**

177 The CYP6P4-236M variant, and its redox partner cytochrome P450 reductase gene (CPR), were

178 expressed in *E. coli* as per standard protocols [32] (Supplementary materials Appendix 2). Initial efforts  
179 to generate recombinant *CYP6AA1* in an *E. coli* system with optimised codon usage failed, and we  
180 therefore used an Sf9-baculovirus-based expression system. Since P450 catalytic activity is dependent  
181 on electrons supplied by NADPH via CPR, insecticide metabolism was assayed with cell pellets of  
182 *CYP6P4/CPR* or *CYP6AA1/CPR* in the presence or absence of NADPH. The depletion of the substrate and  
183 the appearance of metabolites were monitored by reverse-phase HPLC (Supplementary materials  
184 Appendix 3).

185 **Estimation of gene expression of key P450s in triple mutant haplotype**

186 To determine whether the presence of the triple mutant haplotype type was associated with differential  
187 expression of genes, we examined individual females from the BusiaUg colony (Triple mutant Freq.  
188 0.297; 95%CI 0.233-0.370). Two legs were removed from individual mosquitoes for DNA analysis with  
189 the remaining mosquito kept for RNA analysis. DNA was extracted from legs by boiling in STE buffer at  
190 95°C for 90 minutes and individuals were genotyped using the LNA qPCR assays. RNA was then extracted  
191 individually from 8 mosquitoes in each genotypic group - homozygotes for the triple mutant haplotype,  
192 wild-type homozygotes, and heterozygotes, using the Arcturus Picopure RNA isolation kit  
193 (Thermofisher). We then performed SYBR green based qPCR to measure the expression of *Cyp6aa1* and  
194 *Cyp6p4* together with the known resistance-linked variant *Cyp6p3* using the housekeeping genes 40s  
195 ribosomal protein S7 (AGAP010592) and elongation factor Tu (AGAP005128) for normalisation. The  
196 ΔΔCT values were tested for normality and homogeneity of variances using the Shapiro-Wilks test, and  
197 the Bartlett test, respectively. A significant difference in gene expression between the genotypic groups  
198 was determined by a two-tailed two-sample Student's t-test on ΔΔCT values, with a threshold of P=0.05.

199

200 **Results**

201 Hierarchical clustering of 206 Ag1000g haplotypes from *An. gambiae* s.s. from Uganda resulted in  
202 identification of a cluster of 122 haplotypes around the *Cyp6aa/Cyp6p* gene cluster, putatively  
203 representing a swept haplotype in this region. To characterise the signatures of selection in Ugandan  
204 haplotypes around this cluster, we examined the profile of extended haplotype homozygosity around  
205 the position of the *Cyp6p4-236M* SNP and around the CNV in *Cyp6aa1*. In both cases, we found that the  
206 putative swept haplotype had longer stretches of homozygosity than wild-type haplotypes (Figure 2). In  
207 addition, we found that *An. gambiae* s.s. from Uganda had reduced haplotypic diversity along the entire

208 *Cyp6aa/Cyp6p* gene cluster ( $h = 0.339746 \pm 0.005664$  standard error) and a combination of Garud's  $H$   
209 statistics that was indicative of a hard selective sweep in this region (high  $H_{12} = 0.821867 \pm 0.006308$   
210 SE; low  $H_2/H_1 = 0.016779 \pm 0.000228$  SE)[28]. These results confirm that the haplotypes we have  
211 identified have undergone a selective sweep. We then used iterative read mapping of individuals  
212 homozygous for the sweep to search for additional mutations that might be distinctive of the haplotype.  
213 This revealed that a partial copy of a Ty3/Gypsy Zanzibar transposon insertion (termed ZZB-TE), lacking  
214 functional open reading frames, was linked to *Cyp6p4-236M* and *Cyp6aap-Dup1* (Figure 2).

215

#### 216 **The evolution of the ZZB-TE, *Cyp6p4-236M* and *Cyp6aap-Dup1* haplotypes**

217 Based upon Ag1000g data and a time series of collections from Central and East Africa, we were able to  
218 trace the sequence of mutational events (ZZB-TE, *Cyp6p4-236M* and *Cyp6aap-Dup1*) and reconstruct the  
219 evolutionary history of the swept haplotype. Among the Ag1000g data [19], the *Cyp6p4-236M* mutation  
220 was only observed in collections from eastern Uganda (collected in 2012) suggesting that this mutation  
221 originated in the eastern Ugandan/western Kenyan region. In a screen of collections from Uganda and  
222 Kenya predating the Ag1000g collections by eight years (2004) (Fig 3) only the ZZB-TE insertion was  
223 detected, although the sample size was too small ( $n=4$ ) to conclude that the *Cyp6p4-236M* allele was  
224 absent. The *Cyp6p4-236M* mutation was first observed in this region in 2005 (frequency *Cyp6p4-236M*  
225 =0.10) in individuals carrying the ZZB-TE mutation, whilst the *Cyp6aap-Dup1* CNV was first recorded in  
226 2008 (proportion of individuals with Dup1=0.8%). This inferred sequence of events may explain why  
227 ZZB-TE and *Cyp6p4-236M* mutations are in tighter statistical linkage with each other than with *Cyp6aap-*  
228 *Dup1* (Figure 2), despite the closer proximity of ZZB-TE and *Cyp6aap-Dup1* (Figure 1). Given the very  
229 tight association between the ZZB-TE insertion and the *Cyp6p4-236M* SNP, we will henceforth refer to  
230 the *Cyp6p4-236M* (double mutant) haplotype and the *Cyp6aap-Dup1* (triple mutant). The double mutant  
231 haplotype shows a steady increase in frequency between 2004 and 2011 in Kenya (Figure 3); possibly in  
232 response to the introduction and subsequent intensification of bednet distribution programmes [29, 33,  
233 34]. Following its appearance in 2008, the triple mutant haplotype, rapidly increased towards fixation in  
234 both collections from Uganda and Kenya, replacing the double mutant. This haplotype replacement and  
235 the observation that the triple mutant is the only non-wildtype haplotype observed outside  
236 Kenya/Uganda (such as in Tanzania and DRC, Figure 1 and 3) strongly implies an additional selective  
237 advantage to the triple mutant. The time series data from across DRC are particularly striking both in  
238 terms of the speed of increase of the triple mutant but also the north-south heterogeneity, with very  
239 low frequencies in the more southerly provinces (Figure 3).

240

241 **Identifying potential drivers of haplotype frequency increase**

242 The genomic region into which the ZZB-TE inserted does not show histone signals of regulatory  
243 activation (H3K27ac, H3K9ac) or repression (H3K9me3), and ATAC-seq data suggests it is not in an open  
244 chromatin region [35]. However we took two in silico approaches to determine whether the ZZB-TE  
245 insertion (748bp) carried putative regulatory variants. The inserted region had 98.5% sequence identity  
246 to a putative enhancer (2R:45966598-45966822) identified by homology with *Drosophila melanogaster*  
247 [35]. However, despite the similarity, the insertion lacked enhancer-like combination of chromatin  
248 marks identified in [35] and its potential regulatory role in nearby genes is unclear. The second approach  
249 involved screening the ZZB-TE inserted sequence for putative enhancers using iEnhancer-2L[36] and  
250 iEnhancer-EL [37]. In a windowed analysis of 200bp with a 1bp step across the entire length of ZZB-TE  
251 both predicted that some of the windows would have strong enhancer activity, however the windows  
252 were not-concordant, precluding further analysis.

253

254 Given that cytochrome P450 mediated resistance is commonly associated with differential gene  
255 expression we performed transcription studies within the *Cyp6aa/Cyp6p* cluster between the most  
256 contrasting haplotypes, wild-type and triple mutant, present in the BusiaUg colony. The group  
257 homozygous for the triple mutant haplotype significantly overexpressed both *Cyp6aa1* (2.23-fold, 95%  
258 CI: 1.73-2.90, P=0.0003) and *Cyp6p4* (2.57-fold, 95% CI 1.25-5.93, P=0.039) compared to wild-type  
259 individuals. The ratio of expression of *Cyp6aa1* broadly reflected the expected pattern based on  
260 genotype (ie 2:1.5:1 for triple mutant homozygotes: heterozygotes: wild type genotypes, respectively.  
261 Figure 4). As a control we examined a neighbouring, very commonly resistance-associated gene, *Cyp6p3*,  
262 but triple mutant and wild type homozygotes did not differ significantly in expression (1.33 fold, 95% CI  
263 0.64-2.74, P>0.05).

264

265 To investigate whether resistance may be driven at least in part by an effect of the allelic variant on  
266 metabolic activity of CYP6P4, we expressed the wild-type (236I) and mutant (236M) forms in an *E. coli*  
267 based recombinant protein system (Supplementary materials Appendices 2 and 4). Both alleles were  
268 shown to be capable of metabolizing class I (permethrin) and II (deltamethrin) pyrethroids but there was  
269 no evidence that the mutant (236M) or wildtype (236I) alleles had different rates of pyrethroid  
270 depletion. We also expressed the duplicated P450 CYP6AA1, in an *Sf9*-baculovirus protein expression  
271 system. Again, metabolism assays demonstrated that the enzyme was capable of metabolizing both

272 deltamethrin and permethrin (Supplementary materials Appendices 3 and 4). Depletion of  
273 deltamethrin was 36.6% greater (SE= 3.79) in the presence of NADPH than in the control (t-test:  $t=-9.67$ ;  
274 d.f. = 8;  $P= 9.6 \times 10^{-6}$ ), demonstrating that CYP6AA1/CPR is capable of metabolizing deltamethrin *in vitro*.  
275 Similarly, permethrin was metabolised by CYP6AA1/CPR, with permethrin being depleted by 22.4% (SE =  
276 0.63) compared to the control without NADPH (t-test:  $t= -31.08$ ; d.f. = 14;  $P= 2.55 \times 10^{-14}$ ).

277

278 Given clear evidence of increased expression of both *Cyp6aa1* and *Cyp6p4* in the triple mutant  
279 haplotype and the ability of both enzymes to metabolise pyrethroids *in vitro*, we investigated whether  
280 the mutations were significantly associated with resistance *in vivo*. Exposure of *An. gambiae* females  
281 from Busia, Uganda and Nord Ubangi, DRC to new LLINs in cone assays resulted in negligible mortality to  
282 the pyrethroid only LLINs, Olyset and Permanent 2.0 (Figure 5). Simultaneous exposure to pyrethroid  
283 plus the P450 inhibitor PBO in Olyset + and the top of Permanent 3.0 nets resulted in a marked  
284 reduction in resistance, demonstrating that the resistance phenotype is substantially mediated by  
285 P450s. We performed laboratory backcrosses between additional mosquitoes from Busia with the  
286 pyrethroid susceptible Mbita colony, and found that the triple mutant haplotype was significantly  
287 associated with resistance to the most commonly used type II pyrethroids in LLINs: deltamethrin  
288 (Fisher's exact test  $p=3.2 \times 10^{-6}$ ) and alphacypermethrin (Fisher's exact test  $p=5.9 \times 10^{-7}$ ) resistance  
289 although not to permethrin (Fisher's exact test  $p=0.06$ ) nor, as a control, DDT (Fisher's exact test  $p=0.84$ )  
290 (Table 1) in WHO tube assays. Similarly, specimens collected in 2016 from the DRC showed a strong  
291 association between the triple mutant genotype and survival rate 24 hours post-exposure to either  
292 0.05% deltamethrin for 1 hour or 3-minute exposures to deltamethrin-treated sides of a new PermaNet  
293 3.0 net (Table 2). No association was found in samples exposed to permethrin (24 hour WHO tube assay)  
294 or permethrin-treated Olyset Plus nets (3-minute WHO cone assay) (Table 2). Complete linkage of the  
295 three mutants in the BusiaUG colony and the DRC wild caught collections precludes determination of  
296 the relative contribution of each of the three mutations to the resistance phenotype but taken together  
297 these results demonstrate a strong impact of the triple mutant on the efficacy of pyrethroid resistance.

298

## 299 **Discussion**

300 We have identified a sequential series of fitness-augmenting mutations in *An. gambiae* culminating in a  
301 triple-mutant haplotype with a large effect on pyrethroid resistance and which is spreading rapidly  
302 across East and Central Africa. The mutation that is probably the oldest in this series, the insertion of

303 ZZB-TE, was first detected in 2004 in the malaria-endemic area around Lake Victoria, with the *Cyp6p4*-  
304 236M SNP evident in 2005 samples and the third, a duplication in *Cyp6aa1* detected in 2008. In samples  
305 collected only five years later, the triple mutant was detected hundreds of kilometres away in the DRC.  
306 These patterns suggest both a large fitness advantage arising from the triple mutant, and a frightening  
307 speed at which resistance-conferring mutations are able to spread within and across populations.

308 Second generation nets treated with the synergist PBO were shown to be much more effective than  
309 conventional nets in killing mosquitoes in populations where the triple mutant haplotype is present  
310 (Figure 5). Therefore the use of PBO bednets should be prioritised in the regions where this mutation is  
311 present. A strong corollary of this finding comes from the cluster randomised control trial conducted in  
312 Uganda, where the mutation is at high frequency, which demonstrated that malaria parasite prevalence  
313 in children <10 years old (12% vs 14%; Prevalence ratio = 0.84, 95% CI 0.72–0.98; P=0.029) and mean  
314 number of mosquitoes (Density ratio=0.25, 95% CI 0.18–0.3; P <0.0001) per house were significantly  
315 lower in villages that had received PBO LLINs relative to standard LLINs [4]. There is some evidence that  
316 the haplotype may be less strongly associated with resistance to permethrin than deltamethrin (and  
317 perhaps also alphacypermethrin), although both pyrethroids were metabolised by *Cyp6aa1* and *Cyp6p4*.

318 Our results highlight the importance of gene duplications for the evolution of insecticide resistance. In  
319 *An. gambiae*, duplications have recently been shown to be concentrated in regions associated with  
320 metabolic resistance, and over 40 such duplications have been described across the genome [20].  
321 Thirteen different duplications have so far been described that encompass *Cyp6aa1* (Figure 1), both in  
322 West and East Africa and in the two sister-species *An. gambiae* ss and *An. coluzzii* [20]. It seems likely  
323 that these other *Cyp6aa1* duplications are also associated with pyrethroid resistance. For example, in  
324 *An. coluzzii* sampled from a highly insecticide-resistant population from Cote d'Ivoire, greater than 95%  
325 of individuals had *Cyp6aap* duplications (Supplementary materials Appendix 5). Five different  
326 duplications were observed in the collections from 2012 and 2017 and, whilst we detected no  
327 association with pyrethroid resistance, two duplications (*Cyp6aap-Dup7* and *Cyp6aap-Dup14*) showed  
328 significant increases in frequency over time. Moreover the total number of CNVs per sample (measured  
329 as presence of each of the 5 duplications, summed for each sample) increased significantly from an  
330 average of 1.59/ individual in 2012 to 2.08 in 2017 (Mann Whitney U test; P<0.0001); the mean number  
331 of duplications >2 indicates that there are multiple CNVs on the same haplotype. Duplications of the  
332 *Cyp6aa1* orthologue have been found in another important malaria vector, *An. funestus*, from west and  
333 central Africa [21]. The *Cyp6aa1* orthologue in *An. funestus*, which shares an 87% identity with *An.*

334 *gambiae*, was also observed to metabolize permethrin and deltamethrin and, when expressed in  
335 transformed *Drosophila*, was associated with significant increases in resistance to both permethrin and  
336 deltamethrin relative to control mosquitoes [21]. This evolution of multiple *Cyp6aa1* duplications  
337 suggests this is an important Africa wide resistance mechanism

338 There are now several cases of insecticide resistance evolution where an initial mutation in a genomic  
339 region is followed by the spread of additional mutations on the resistant haplotype background [14, 38-  
340 42]. It is not yet clear whether the sequence of mutations that we have identified rely on each-other for  
341 effect, and thus could only have spread sequentially, or whether each additional mutation coincidentally  
342 appeared on the background of an already common mutant haplotype. In the case of *Cyp6p4-236M* and  
343 *Cyp6aap-Dup1* it seems that the latter is more likely, although we cannot exclude the possibility that the  
344 duplication affects the regulation of *Cyp6p4*. In contrast, the putative enhancer inserted with the ZZB  
345 transposon may affect either or both of *Cyp6p4* and *Cyp6aa1*, and may thus interact with the other two  
346 mutations in ways that have yet to be determined. Transposable elements can sometimes affect gene  
347 expression of neighbouring genes [38] and are abundant in mosquito genomes [43, 44]. Interestingly, in  
348 the common house mosquito, *Culex pipiens*, TEs have been found in the flanking regions of the *Ester*  
349 locus, a genomic region in which many independent gene duplications have arisen and spread  
350 worldwide in response to selection from organophosphates [45]. Clearly, both TEs and gene  
351 duplications are an understudied, yet common source of variation that may have important implications  
352 for vector control efforts. The appearance and rapid spread of the three mutations described here is  
353 broadly coincident with the scale up of LLIN coverage in DRC, Kenya and Uganda. The haplotype is a  
354 strongly predictive marker of high-level resistance to pyrethroids, is easily screened with a single  
355 diagnostic assay and we suggest should be used for both insecticide resistance monitoring strategies and  
356 for informing LLIN selection.[6, 29, 46].

357

### 358 **Acknowledgements**

359 This work was supported by the National Institute of Allergy and Infectious Diseases ([NIAID] R01-  
360 AI116811) with additional support from the Medical Research Council (MR/P02520X/1). The latter grant  
361 is a UK-funded award and is part of the EDCTP2 programme supported by the European Union. HN and  
362 AO were supported by Wellcome Trust MSc Training Fellowships in Public Health and Tropical Medicine.  
363 SI is funded by the U.S. President's Malaria Initiative. CM was supported by the Bill and Melinda Gates  
364 Foundation through the WHO (Award #54497) and by the Biovision Foundation (Grant No.BV HH-07).

365 JLB is supported by DELTAS Africa Initiative grant # DEL-15-011 to THRIVE-2. The DELTAS Africa Initiative  
366 is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating  
367 Excellence in Science in Africa (AES) and supported by the New Partnership for Africa's Development  
368 Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust grant #  
369 107742/Z/15/Z and the UK government. SI is funded by the U.S. President's Malaria Initiative. The  
370 findings and conclusions in this paper are those of the authors and do not necessarily represent the  
371 official position of CDC, the NIAID, the National Institutes of Health or the other donors.

372


373 **Author contributions**

374 HN, AvH, MJIP, DW and MJD designed the study; HN, AvT, AO, DP, SCN, AL conducted lab and insectary  
375 experiments; HN, AvH, SCN, AL, ERL, ST, XG-B, DM, MJD performed analysis; AO, AL, FW, EM, FA, SI, BK,  
376 DW, CM conducted field collections and phenotyping; HN, ERL, DW, MJD wrote the manuscript with  
377 input from all authors; JLB, CM, MJIP, DW and MJD supervised the study; all authors approved the final  
378 version of the manuscript.

379

380

381 **Tables and figures**




382

383

384 **Figure 1. Schematic of the mutational events around the *Cyp6aa/Cyp6p* cluster on chromosome 2R in**  
385 ***Anopheles gambiae*. Upper panel shows the three mutational events observed in East and Central**  
386 **African samples. Orange indicates the genes/ transposable elements involved and the blue band the**  
387 **extent of the *Cyp6aa*-*Dup1* CNV. The lower panel, redrawn from [20], shows the genomic extent and**  
388 **geographic distribution of the CNVs that have been observed around the *Cyp6aa/Cyp6p* cluster, 13 out**  
389 **of 15 include *Cyp6aa1*.The dark blue shading on the map indicates the geographic extent of *Cyp6aa*-**  
390 ***Dup1*. Data from Uganda, Kenya and DRC are reported extensively in the main text, in addition 27.4%**  
391 **(n=84) of *Anopheles gambiae* females sampled from northern Tanzania in 2018 were triple mutant**  
392 **carriers.**

393

394



395

396

**Figure 2. Selective sweep around the *Cyp6aa*/*Cyp6p* cluster in *Anopheles gambiae* from Uganda.**


398 Upper panel Haplotype contingency for the selective sweep ("Sweep"), *Cyp6p4-236M* SNP ("P4") and  
399 the *Cyp6aa1-Dup1* ("Dup1"). Each vertical bar represents a single haplotype, colour-coded to show  
400 whether it is a copy of the swept haplotype (blue) and whether it carries the SNP (purple), the TE  
401 insertion (green) and the duplication (orange). The swept haplotype and the *Cyp6p4-236M* SNP overlap  
402 almost completely, while the duplication is found on a subset of these haplotypes. Lower panel  
403 Extended Haplotype Homozygosity (EHH) plots around the *CYP6P4-236M* and *CYP6AA1-Dup1* variants  
404 show slower loss of homozygosity in the swept haplotypes than in the wild-type.

405

406


407

408




409  
410  
411

412 **Figure 3. Observed and modelled changes in *Cyp6aa/Cyp6p* haplotype frequencies over time in**  
413 ***Anopheles gambiae* s.s. populations from DRC, Kenya and Uganda.** Upper panel shows mutation  
414 frequency estimates derived from wild caught individuals from Kabondo, DRC; western Kenya and  
415 eastern Uganda. The 95% CIs for each observed data point were calculated according to[47]. Expected  
416 data generated from simultaneous maximum likelihood estimates of initial frequency and selection and  
417 dominance coefficients which were then used to parameterize standard recursive allele frequency  
418 change equation. The lower panel shows data from DRC tracking the emergence and spread of the triple  
419 mutant haplotype. Triangles indicate collection locations within each district. The red triangle shows the  
420 Kabondo sample site for which there was the most complete time series.



421  
422 **Figure 4. Gene expression analysis of *Cyp6p4* and *Cyp6aa1* in genotyped *Anopheles gambiae* females.**  
423 Relative fold change for *Cyp6p4* (Panel A) and *Cyp6aa1* (Panel B), comparing individuals homozygous for  
424 the swept triple mutant haplotype and heterozygotes in the BusiaUG colony to wild-type individuals.  
425 95% confidence intervals are shown. Asterisks indicate statistical significance in two-tailed students t-  
426 tests; \*\*\* P ≤ 0.001, \*\* P ≤ 0.01, \* P ≤ 0.05.

427



428

429

430 **Figure 5. Patterns of insecticide resistance in *Anopheles gambiae* following exposure to permethrin  
431 and deltamethrin treated nets.** Female *Anopheles gambiae* s.s. from the Democratic Republic of Congo  
432 (DRC) and Uganda exhibited very high resistance (low % mortality) in WHO cone assays to permethrin  
433 (Olyset) and deltamethrin (PermaNet 2.0) LLINs. There was an increase in mortality following exposure  
434 to an increased concentration of deltamethrin (PermaNet 3.0 Side) and very high mortality following  
435 exposure to pyrethroid plus the P450 inhibitor piperonyl butoxide (PBO) Olyset+ and PermaNet 3.0 Top.  
436 95% confidence intervals are shown.

**Table 1. Association between insecticide susceptibility as determined by WHO tube bioassay and triple mutant genotype in female *Anopheles gambiae* from a cross between BusiaUG and Mbita colonies. <sup>a</sup>Odds ratios for allelic test and associated 95%CI**

Insecticide	Phenotype	Wildtype homozygote	Heterozygote	Triple mutant homozygote	Test and p value
$\alpha$ -Cypermethrin n=146	Alive	1	32	24	Genotypic p=5.92x10 <sup>-7</sup>
	Dead	14	68	7	Allelic p=6.34x10 <sup>-5</sup> ; OR <sup>a</sup> 2.74 (1.63-4.69)
Deltamethrin n=60	Alive	0	0	8	Genotypic p=3.21x10 <sup>-6</sup>
	Dead	15	26	11	Allelic- Cannot be calculated
Permethrin n=53	Alive	1	18	7	Genotypic p=0.059
	Dead	5	20	2	Allelic p=0.08; OR 1.99 (0.86-4.67)
DDT n=65	Alive	0	14	1	Genotypic p=1
	Dead	3	45	2	Allelic p=0.84; OR 1.19 (0.48-2.94)

**Table 2. Association between insecticide susceptibility as determined by WHO tube bioassay or WHO net bioassay and triple mutant genotype in wild-caught, female *Anopheles gambiae* from three locations in Nord Ubangi Province, Democratic Republic of Congo. <sup>a</sup>Odds ratios for allelic test and associated 95%CI**

Site	Insecticide	Bioassay	Phenotype	Wildtype homozygote		Triple mutant homozygote	Test and p value
					Heterozygote		
Fiwa	Permethrin	Tube	Alive	5	42	30	Genotypic p=0.63
			Dead	8	49	27	Allelic p=0.42; OR <sup>a</sup> 1.23 (0.76-2.00)
Fiwa	Deltamethrin	Tube	Alive	6	14	18	Genotypic p=6.21x10 <sup>-3</sup>
			Dead	7	27	6	Allelic p=0.04; OR 2.01 (1.01-4.06)
Bassa	Permethrin	Tube	Alive	1	19	18	Genotypic p=0.79
			Dead	2	32	23	Allelic p=0.63; OR 1.21 (0.61-2.43)
Bassa	Deltamethrin	Tube	Alive	0	3	16	Genotypic p=4.02x10 <sup>-3</sup>
			Dead	1	16	11	Allelic p=5.71x10 <sup>-3</sup> ; OR 5.44 (1.41-31.28)
Pwamba	Deltamethrin	Tube	Alive	7	9	7	Genotypic p=0.066
			Dead	9	9	1	Allelic p=0.02; OR 2.93 (1.07-8.39)
Fiwa	Olyset Plus	Net	Alive	6	21	30	Genotypic p=0.82
			Dead	6	15	28	Allelic p=0.88; OR 0.93 (0.49-1.77)
Fiwa	Permanet 3.0	Net	Alive	5	26	24	Genotypic p=5.61x10 <sup>-4</sup>
			Dead	30	51	19	Allelic p=1.4x10 <sup>-4</sup> ; OR 2.56 (1.54-4.31)

## References

1. Ranson, H. and N. Lissenden, *Insecticide resistance in African Anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control.* . Trends in Parasitology, 2016. **32**(3): p. 187-196.
2. WHO, *World malaria report 2019*, W.H. Organization, Editor. 2019, World Health Organization: Geneva. p. 232.
3. Kleinschmidt, I., et al., *Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study*. Lancet Infectious Diseases, 2018. **18**(6): p. 640-649.
4. Staedke, S.G., Gonahasa, S., Dorsey, G., Kamya, M.R., Maiteki-Sebuguzi, C., Lynd, A., Katureebe, A., Kyohere, M., Mutungi, P., Kigozi, S.P., Opigo, J., Hemingway, J., and M.J. Donnelly, *Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign*. Lancet, 2020(395): p. 1292-303.
5. Killeen, G.F. and H. Ranson, *Insecticide-resistant malaria vectors must be tackled*. Lancet, 2018. **391**(10130): p. 1551-1552.
6. The Anopheles gambiae 1000 Genomes Consortium, *Genome variation and population structure among 1142 mosquitoes of the African malaria vector species Anopheles gambiae and Anopheles coluzzii*. Genome Research, 2020. **30**(10): p. 1533-1546.
7. Mugenzi, L.M.J., et al., *Cis-regulatory CYP6P9b P450 variants associated with loss of insecticide-treated bed net efficacy against Anopheles funestus*. Nature Communications, 2019. **10**.
8. Donnelly, M.J., A. Isaacs, and D. Weetman, *Identification, validation, and application of molecular diagnostics for insecticide resistance in malaria vectors*. Trends in Parasitology, 2016. **32**(3): p. 197-206.
9. Mitchell, S.N., et al., *Metabolic and Target-Site Mechanisms Combine to Confer Strong DDT Resistance in Anopheles gambiae*. PLoS ONE, 2014. **9**(3).
10. Weetman, D., Wilding, C.S., Neafsey, D.E., Muller, P., Ochomo, E., Isaacs, A.T., Steen, K., Rippon, E.J., Morgan, J.C., Mawjee, H.D., Rigden, D.J., Okedi, L.M., Donnelly, M.J. , *Candidate-gene based GWAS identifies reproducible DNA markers for metabolic pyrethroid resistance from standing genetic variation in East African Anopheles gambiae*. Scientific Reports, 2018. **8**: p. e2920.
11. Weetman, D. and M.J. Donnelly, *Evolution of insecticide resistance diagnostics in malaria vectors*. Transactions of The Royal Society of Tropical Medicine and Hygiene, 2015. **109**(5): p. 291-293.
12. Bhatt, S., et al., *The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015*. Nature, 2015. **526**(7572): p. 207-+.
13. Hancock, P.A., et al., *Mapping trends in insecticide resistance phenotypes in African malaria vectors*. PLoS Biology, 2020. **18**(6): p. e3000633.
14. Clarkson, C.S., et al., *The genetic architecture of target-site resistance to pyrethroid insecticides in the African malaria vectors Anopheles gambiae and Anopheles coluzzii*. bioRxiv, 2018(<https://doi.org/10.1101/323980>).
15. Müller, P., et al., *Field-caught permethrin-resistant Anopheles gambiae overexpress CYP6P3, a P450 that metabolises pyrethroids*. PLoS Genetics, 2008. **4**(11): p. e1000286.
16. Weedall, G.D., et al., *A cytochrome P450 allele confers pyrethroid resistance on a major African malaria vector, reducing insecticide-treated bednet efficacy*. Science Translational Medicine, 2019. **11**(484).

17. Protopopoff, N., et al., *Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial*. Lancet, 2018. **391**(10130): p. 1577-1588.
18. Lynd, A., et al., *LLIN Evaluation in Uganda Project (LLINEUP) – A cross-sectional survey of species diversity and insecticide resistance in 48 districts of Uganda*. Parasites and Vectors, 2019. **12**: p. e94.
19. The *Anopheles gambiae* 1000 Genomes Consortium, *Natural diversity of the malaria vector Anopheles gambiae*. Nature (London), 2017. **552**: p. 96-100.
20. Lucas, E., et al., *Whole genome sequencing reveals high complexity of copy number variation at insecticide resistance loci in malaria mosquitoes*. Genome Research, 2019. <https://doi.org/10.1101/399568> (29): p. 1250-1261
21. Ibrahim, S.S., et al., *Pyrethroid resistance in the major malaria vector Anopheles funestus is exacerbated by overexpression and overactivity of the P450 CYP6AA1 across Africa*. Genes, 2018. **9**(3): p. 17.
22. Zhou, D., et al., *Genomic analysis of detoxification supergene families in the mosquito Anopheles sinensis*. PLoS One, 2015. **10**(11): p. e0143387.
23. Kwiatkowska, R.M., et al., *Dissecting the mechanisms responsible for the multiple insecticide resistance phenotype in Anopheles gambiae s.s., M form, from Vallee du Kou, Burkina Faso*. Gene, 2013. **519**(1): p. 98-106.
24. Mitchell, S., et al., *Identification and validation of a gene causing cross-resistance between insecticide classes in Anopheles gambiae from Ghana*. Proceedings of the National Academy of Sciences of the United States of America, 2012. **109**: p. 6147-6152
25. Edi, C.V., et al., *CYP6 P450 enzymes and ACE-1 duplication produce extreme and multiple insecticide resistance in the malaria mosquito Anopheles gambiae*. PLoS Genetics, 2014. **10**(3): p. e1004236-e1004236.
26. Vontas, J., et al., *Rapid selection of a pyrethroid metabolic enzyme CYP9K1 by operational malaria control activities*. Proceedings of the National Academy of Sciences of the United States of America, 2018. **115**(18): p. 4619-4624.
27. Miles, A., et al., *cggh/scikit-allel*. 2019, Zenodo.
28. Garud, N.R., et al., *Recent selective sweeps in North American Drosophila melanogaster show signatures of soft Sweeps*. PLOS Genetics, 2015. **11**(2): p. e1005004.
29. Wat'senga, F., et al., *Intensity of pyrethroid resistance in Anopheles gambiae before and after a mass distribution of insecticide-treated nets in Kinshasa and in 11 provinces of the Democratic Republic of Congo*. Malaria Journal, 2020. **19**(1): p. e169.
30. Lynd, A., et al., *Insecticide resistance in Anopheles gambiae from the northern Democratic Republic of Congo, with extreme knockdown resistance (kdr) mutation frequencies revealed by a new diagnostic assay*. Malaria Journal, 2018. **17**.
31. Lynd, A., Weetman, D., Barbosa, S., Yawson, A.E., Mitchell, S., Pinto, J., Hastings, I. and Donnelly, M.J., *Field, genetic and modelling approaches show strong positive selection acting upon an insecticide resistance mutation in Anopheles gambiae s.s.* Molecular Biology and Evolution, 2010. **27**: p. 1117-1125.
32. Yunta, C., et al., *Cross-resistance profiles of malaria mosquito P450s associated with pyrethroid resistance against WHO insecticides*. Pesticide Biochemistry and Physiology, 2019. **161**: p. 61-67.
33. Yeka, A., et al., *Malaria in Uganda: Challenges to control on the long road to elimination I. Epidemiology and current control efforts*. Acta Tropica, 2012. **121**(3): p. 184-195.
34. Ministry of Health, R.o.K., *Insecticide Resistance Management Plan, Kenya 2020 – 2024*. 2019, Ministry of Health, Republic of Kenya.

35. Ruiz, J.L., L.C. Ranford-Cartwright, and E. Gómez-Díaz, *The regulatory genome of the malaria vector Anopheles gambiae: integrating chromatin accessibility and gene expression*. bioRxiv, 2020: p. 2020.06.22.164228.
36. Liu, B., et al., *iEnhancer-2L: a two-layer predictor for identifying enhancers and their strength by pseudo k-tuple nucleotide composition*. Bioinformatics, 2015. **32**(3): p. 362-369.
37. Liu, B., et al., *iEnhancer-EL: identifying enhancers and their strength with ensemble learning approach*. Bioinformatics, 2018. **34**(22): p. 3835-3842.
38. Schmidt, J.M., et al., *Copy number variation and transposable elements feature in recent, ongoing adaptation at the Cyp6g1 locus*. PLoS Genetics, 2010. **6**(6): p. e1000998.
39. Jones, C., et al., *Footprints of positive selection associated with a novel mutation (N1575Y) in the voltage gated sodium channel of Anopheles gambiae*. Proceedings of the National Academy of Sciences of the United States of America, 2012. **109**: p. 6614-6619.
40. Djogbenou, L., et al., *Ace-1 duplication in Anopheles gambiae: a challenge for malaria control*. Malaria Journal, 2009. **8**.
41. Boakye, D.A., et al., *Patterns of household insecticide use and pyrethroid resistance in Anopheles gambiae sensu stricto (Diptera: Culicidae) within the Accra metropolis of Ghana*. African Entomology, 2009. **17**(2): p. 125-130.
42. Grau-Bové, X., et al., *Evolution of the insecticide target Rdl in African Anopheles is driven by interspecific and interkaryotypic introgression*. bioRxiv, 2020: p. 2019.12.17.879775.
43. Neafsey, D.E., et al., *Highly evolvable malaria vectors: The genomes of 16 Anopheles mosquitoes*. Science, 2015. **347**(6217): p. 43-+.
44. Nene, V., et al., *Genome sequence of Aedes aegypti, a major arbovirus vector*. Science, 2007. **316**(5832): p. 1718-1723.
45. Buss, D.S. and A. Callaghan, *Molecular comparisons of the Culex pipiens (L.) complex esterase gene amplicons*. Insect Biochemistry and Molecular Biology, 2004. **34**(5): p. 433-441.
46. Rugnao, S., et al., *LLIN Evaluation in Uganda Project (LLINEUP): factors associated with childhood parasitaemia and anaemia 3years after a national long-lasting insecticidal net distribution campaign: a cross-sectional survey*. Malaria Journal, 2019. **18**: p. e207.
47. Newcombe, R.G., *Two-sided confidence intervals for the single proportion: comparison of seven methods*. Statistics in Medicine, 1998. **17**: p. 857-872.